Endosense believes that catheter ablation promises to offer physicians and their AF patients a less invasive approach with the potential for better outcomes and fewer negative side effects than traditional AF therapies. Our focus is on improving the efficacy, safety and reproducibility of what has historically been a very complex and unpredictable procedure.
In traditional catheter ablation, the electrophysiologist has threaded an ablation catheter – a long, thin, flexible tube – to the upper chambers of the heart to create “lesions,” or small burns, on the heart wall. These burns are intended to disrupt the abnormal electrical activity and restore normal heart rhythm. However, a key challenge in the procedure has been that the physician has had no reliable way of determining how much force he or she is applying to the heart wall during lesion creation. If too much force is applied, the catheter tip may damage the heart wall. If too little force is applied, the procedure will not be effective.
Endosense’s solution to this clinical challenge is the TactiCath®, the first and only force-sensing ablation catheter that provides physicians with an objective, real-time assessment of contact force between the catheter tip and the beating heart wall during the catheter ablation procedure. This means that he or she will use just the right amount of force to create just the right lesions, preventing the potential for tissue damage and the need for repeat procedures.
The TactiCath has been the subject of extensive pre-clinical and clinical testing, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact force sensing during catheter ablation.